SUPN - SUPERNUS PHARMACEUTICALS, INC.


53.87
-0.400   -0.743%

Share volume: 643,456
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%

$54.27
-0.40
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Income statement Balance sheet Cash flow To see more then 2 years history Buy Premium
View ratios

Fiscal Date 03-31-2024 06-30-2024 09-30-2024 12-31-2024 03-31-2025 06-30-2025 09-30-2025 12-31-2025
Fiscal Quarter Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Report Date 05-08-2024 08-06-2024 11-04-2024 02-25-2025 05-06-2025 08-05-2025 11-06-2025 03-02-2026
Total revenue 143.644 M 168.325 M 175.689 M 174.159 M 149.824 M 165.453 M 192.103 M 211.572 M
Cost of revenue 16.309 M 17.916 M 17.583 M 26.098 M 15.763 M 16.827 M 18.965 M 23.007 M
Gross profit 127.335 M 150.409 M 158.106 M 148.061 M 134.061 M 148.626 M 173.138 M 188.565 M
    18.12% 5.12% -6.35% -9.46% 10.86% 16.49% 8.91%  
Operating expenses 111.446 M 112.087 M 98.789 M 108.056 M 116.871 M 115.666 M 209.044 M 150.217 M
Selling general and admin 86.516 M 85.904 M 69.753 M 79.409 M 89.944 M 93.551 M 179.678 M 122.390 M
Research and development 24.930 M 26.183 M 29.036 M 28.647 M 26.927 M 22.115 M 29.366 M 27.827 M
Total expenses 147.892 M 127.840 M 117.261 M 126.656 M 144.317 M 136.485 M 233.369 M 192.502 M
    -13.56% -8.28% 8.01% 13.94% -5.43% 70.99% -17.51%  
Operating income -4.248 M 22.569 M 40.845 M 21.405 M -10.256 M 12.141 M -60.231 M -3.937 M
Ebit -4.248 M 26.302 M 44.943 M 26.382 M -5.831 M 16.669 M -57.954 M -1.914 M
Pretax income 243.000 K 26.302 M 44.943 M 26.382 M -5.831 M 16.669 M -57.954 M -1.914 M
    10,723.87% 70.87% -41.30% -122.10% -385.87% -447.68% -96.70%  
Income tax 119.000 K 6.386 M 6.446 M 11.054 M 5.996 M -5.830 M -12.837 M 2.191 M
Net income basic 124.000 K 0.000 0.000 0.000 0.000 0.000 0.000 0.000
    -100.00%              
Net income 124.000 K 19.916 M 38.497 M 15.328 M -11.827 M 22.499 M -45.117 M -4.105 M
    15,961.29% 93.30% -60.18% -177.16% 290.23% -300.53% 90.90%